PD-L1 Antikörper (AA 39-191)
Kurzübersicht für PD-L1 Antikörper (AA 39-191) (ABIN6939569)
Target
Alle PD-L1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 39-191
-
Aufreinigung
- Purified by Protein A/G
-
Immunogen
- Recombinant fragment of human CD274 protein (around aa39-191) (exact sequence is proprietary)
-
Isotyp
- IgG1 kappa
-
-
-
-
Applikationshinweise
-
Positive Control: Jurkat, HEK293 or HepG2 cells. Lung SqCC, Cervical or Breast Carcinoma.
Known Application: ELISA (For coating, order antibody without BSA),Western Blot (1-2 μg/mL),Optimal dilution for a specific application should be determined.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 200 μg/mL
-
Buffer
- 10 mM PBS with0.05 % BSA & 0.05 % azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
-
Haltbarkeit
- 24 months
-
-
- PD-L1 (CD274 (PD-L1))
-
Andere Bezeichnung
- CD274
-
Hintergrund
- Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20 % and 15 % identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.
-
Molekulargewicht
- 37-50kDa
-
Gen-ID
- 29126
-
UniProt
- Q9NZQ7
-
Pathways
- Cancer Immune Checkpoints
Target
-